| Literature DB >> 26427446 |
Conor Daly1, Jun Yin2, Breandán N Kennedy3.
Abstract
Previous studies report that retinitis pigmentosa (RP) patients treated with the histone deacetylase inhibitor (HDACi) valproic acid (VPA) present with improved visual fields and delayed vision loss. However, other studies report poor efficacy and safety of HDACi in other cohorts of retinal degeneration patients. Furthermore, the molecular mechanisms by which HDACi can improve visual function is unknown, albeit HDACi can attenuate pro-apoptotic stimuli and induce expression of neuroprotective factors. Thus, further analysis of HDACi is warranted in pre-clinical models of retinal degeneration including zebrafish. Analysis of HDAC expression in developing zebrafish reveals diverse temporal expression patterns during development and maturation of visual function.Entities:
Keywords: Histone deacetylase; Histone deacetylase inhibtors; Retinal degeneration; Retinitis pigmentosa; Zebrafish
Mesh：
Substances：
Year: 2016 PMID： 26427446 DOI： 10.1007/978-3-319-17121-0_61
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622